Sugi Predict

Sugi Predict / Compounds / SCHEMBL21884438

SCHEMBL21884438

SCHEMBL21884438

N#Cc1ccc(O)c(C(=O)NC(=N)N)c1-c1cccc(Cl)c1F

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPIA P62937 6/20 0.33
▸ HSD17B1 P14061 1/20 0.33
▸ HSD17B2 P37059 1/20 0.33
▸ P2RX1 P51575 1/20 0.33
▸ KMO O15229 2/20 0.32
▸ TAS1R3 Q7RTX0 1/20 0.32
▸ TAS1R1 Q7RTX1 1/20 0.32
▸ TAS1R2 Q8TE23 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ CYP2C8 P10632 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ PIP4K2A P48426 1/20 0.32
▸ AR P10275 1/20 0.32
▸ EPAS1 Q99814 1/20 0.32
▸ MEN1 O00255 2/20 0.31
▸ KMT2A Q03164 2/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ NPC1 O15118 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ TP53 P04637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21884572 0.89 TAS1R3 (0.33) PPIAP2RX1TAS1R3TAS1R1TAS1R2
SCHEMBL23854877 0.89 PPIA (0.39) PPIAHSD17B1HSD17B2ARMEN1
SCHEMBL21884434 0.89 L3MBTL1 (0.38) PPIATAS1R3TAS1R1TAS1R2AR
SCHEMBL21884394 0.87 MAPT (0.34) PPIATAS1R3TAS1R1TAS1R2EPAS1
SCHEMBL21884443 0.87 PPIA (0.38) PPIAP2RX1ARMEN1KMT2A
SCHEMBL21885698 0.87 PPIA (0.33) PPIAPIP4K2AARHSD17B14
SCHEMBL21884360 0.86 MEN1 (0.33) PPIAP2RX1ARMEN1KMT2A
SCHEMBL21884352 0.85 AR (0.42) PPIAHSD17B1HSD17B2P2RX1AR
SCHEMBL21884383 0.85 L3MBTL1 (0.38) TAS1R3TAS1R1TAS1R2CYP3A4CYP2C9
SCHEMBL21884788 0.84 PPIA (0.40) PPIAARMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210371403-A1 SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS JNANA THERAPEUTICS INC. 2021-12-02 — — US disclosed
US-20210371403-A1 SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS JNANA THERAPEUTICS INC. 2021-12-02 — — US disclosed
US-20210299070-A1 METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY JNANA THERAPEUTICS INC. 2021-09-30 — — US disclosed
US-20210299070-A1 METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY JNANA THERAPEUTICS INC. 2021-09-30 — — US disclosed
WO-2020061473-A1 SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS JNANA THERAPEUTICS, INC. (US) 2020-03-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210299070-A1 METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY SLC19A1, SLC1A5, SLC1A2 PPIA 1961/4885HSD17B1 1039/4885HSD17B2 1221/4885
US-20210371403-A1 SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS SNRPE, G3BP1, G3BP2 PPIA 2399/4885HSD17B1 4048/4885HSD17B2 4093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.